Lead Product(s) : RC-0315
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Preclinical
Sponsor : Qureight
Deal Size : Undisclosed
Deal Type : Collaboration
Remedy Cell, Qureight use AI in Phase 1b RC-0315 Trial for IPF Treatment
Details : The collaboration aims to validate RC-0315, which is being evaluated for treating patients suffering from idiopathic pulmonary fibrosis.
Product Name : RC-0315
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
March 12, 2025
Lead Product(s) : RC-0315
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Preclinical
Sponsor : Qureight
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : MesenCure
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Wize Pharma's Strategic Transaction Partner Bonus BioGroup to Present MesenCure Data
Details : Treatment with MesenCure reduced fluid in the lungs by 47% compared to untreated subjects, and significantly increased blood lymphocyte counts, which play a key role in fighting viruses.
Product Name : Undisclosed
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
May 27, 2020
Lead Product(s) : MesenCure
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Activated Mesenchymal Stromal Cell
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Bonus reported that following treatment with MesenCure, the microscopic appearance of treated lungs was similar to healthy lungs, and a significant improvement in additional parameters was achieved.
Product Name : Undisclosed
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
May 18, 2020
Lead Product(s) : Activated Mesenchymal Stromal Cell
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable